Format

Send to

Choose Destination
J Bone Oncol. 2017 Nov 26;10:36-40. doi: 10.1016/j.jbo.2017.11.005. eCollection 2018 Mar.

Advances in limb salvage treatment of osteosarcoma.

Author information

1
Department of Medical, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No 16, Jichang Road, Baiyun District, Guangzhou, Guangdong 510405, People's Republic of China.
2
Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of Orthopaedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, People's Republic of China.

Abstract

Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.

KEYWORDS:

Chemotherapy; Infection; Limb salvage; Osteosarcoma; Surgery

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center